Boston medical device maker InspireMD (OTC:NSPR) got the go-ahead from European regulators to resume sales of its MGuard Prime EPS stent after it was take off the market earlier this year.
InspireMD
InspireMD pulls MGuard Prime EPS stent, suspends U.S. trial
Cook Medical continues to shuffle management | Personnel Moves
Cook Medical named Rob Lyles executive vice president, the latest move in a larger management shift at the Indiana medtech maker.
Lyles was formerly vice president of Cook’s peripheral intervention division. He has been with the company since 2003 and was named division VP in 2007. Lyles’ promotion follows the advancement of Pete Yonkman to president of the Cook Medical. Mark Breedlove, a 19-year veteran of Cook Medical, will succeed Lyles as VP of the peripheral intervention division.
InspireMD raises $10M, files to raise $75M more
Accellent promotes Friedman to president & COO | Personnel Moves
Accellent names new COO, president
Massachusetts medtech manufacturer Accellent Inc. shuffled its C-Suite, promoting Jeremy Friedman from CFO to president and COO of the cardio & vascular business, in addition to his duties as executive vice president.
InspireMD pares manufacturing, hires European distribution company
States questioned for selling patient records, risking privacy | MassDevice.com On Call
MASSDEVICE ON CALL — Health records from hospitals in 26 states that was later sold to researchers and companies contained data that could be linked to individuals, raising concerns about how differing levels of compliance with data redaction standards put patients’ privacy at risk, Bloomberg reported.
EuroPCR: New data showing reduced mortality in InspireMD’s MGuard stent trial
InspireMD (OTC:NSPR) presented new 6-month follow up data for its MASTER trial showing lower mortality rates in patients treated with its MGuard stent. The company’s findings were presented today at the STEMI symposium of the annual EuroPCR meeting in Paris, France.
The trial measured all-cause mortality for patients treated with the company’s MGuard stents compared to a control group treated with bare metal stents or drug-eluting stents.
InspireMD soars on FDA green light to begin clinical trial
InspireMD raises $23M for MGuard stent | Wall Street Beat
InspireMD wins CE Mark for MGuard blood clot stent
InspireMD (OTC:NSPR) said it won a nod from European regulators for its MGuard embolic protection stent, designed to prevent strokes after carotid artery stenting procedures.
The Tel-Aviv-based medical device company said the MGuard device is wrapped with its MicroNet mesh to prevent embolisms – blood clots – from occurring during and after the placement of a carotid stent.